Nerve Growth Factor Market: Epidemiology, Therapies, Companies, DelveInsight | Dompe farmaceutici S.p.A., Pfizer Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Merck KGaA, Sanofi, Promega

DelveInsight's "Nerve growth factor (NGF) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Nerve growth factor, historical and forecasted epidemiology as well as the Nerve growth factor market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Nerve Growth Factor therapies are expected to boost the Nerve Growth Factor Market in the upcoming years.

DelveInsight has launched a new report on "Nerve Growth Factor - Market Insights, Epidemiology, and Market Forecast-2034 [https://www.delveinsight.com/report-store/nerve-growth-factor-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" that delivers an in-depth understanding of the Nerve Growth Factor, historical and forecasted epidemiology as well as the Nerve Growth Factor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for a detailed report @ https://www.delveinsight.com/sample-request/nerve-growth-factor-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Nerve Growth Factor Market Report:

*
Zhao et al. (2022) reported that osteoarthritis (OA) is the third leading cause of disability, affecting around 350 million people globally. Nerve growth factor (NGF) plays a role in pain signal transmission and nociceptor receptor gene expression, acting as a nociceptor sensitizer. It has been explored as a potential target for OA pain treatment. The study found that the risk of rapidly progressive OA at the final follow-up ranged from 0.7% to 6.3% with anti-NGF monoclonal antibody treatment, compared to 0.2% to 1.2% with the active comparator (overall 4.4% vs. 0.8%).

*
Key Nerve Growth Factor companies such as Dompe farmaceutici S.p.A., Pfizer Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Merck KGaA, Sanofi, Promega Corporation, and Alomone Labs, and others are evaluating new drugs for Nerve Growth Factor to improve the treatment landscape.

*
In October 2023, the FDA granted Fast Track designation to NVG-291, a therapeutic peptide targeting nervous system repair mechanisms, for treating individuals with spinal cord injuries. This designation aims to expedite the development and review process for drugs addressing serious conditions with unmet medical needs.

Key benefits of the Nerve Growth Factor market report:

*
Nerve Growth Factor market report covers a descriptive overview and comprehensive insight of the Nerve Growth Factor Epidemiology and Nerve Growth Factor market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

*
The Nerve Growth Factor market report provides insights on the current and emerging therapies.

*
Nerve Growth Factor market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Nerve Growth Factor market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Nerve Growth Factor market.

Got queries? Click here to know more about the Nerve Growth Factor Market Landscape [https://www.delveinsight.com/report-store/nerve-growth-factor-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Nerve Growth Factor Overview

Nerve Growth Factor (NGF), a type of neurotrophin, is vital for the proper functioning of the nervous, immune, and endocrine systems. As the first neurotrophin to be discovered, NGF is essential for neural development, differentiation, and maintenance in both the central (CNS) and peripheral nervous systems (PNS) throughout life. It is a pleiotropic molecule, produced and utilized by a variety of cell types, including both structural and immune cells.

NGF exerts its effects via two main receptors: the high-affinity trkANGFR, which possesses tyrosine kinase activity, and the low-affinity p75NTR, a pan-neurotrophin receptor. While trkANGFR generally promotes cell survival and growth, p75NTR can trigger apoptotic pathways when trkANGFR levels are low. The interplay between these receptors determines NGF's overall influence on target cells.

Impaired NGF transport can result in nerve damage, as observed in peripheral neuropathies. NGF and its receptors are also implicated in tumor cell proliferation, differentiation, and migration in various cancers. Moreover, NGF plays a central role as a mediator of peripheral pain.

Nerve Growth Factor Market Outlook

The Nerve Growth Factor market is expected to evolve significantly in the coming years, driven by the anticipated introduction of emerging therapies from leading companies such as Dompe farmaceutici S.p.A., Pfizer Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Merck KGaA, Sanofi, Promega Corporation, Alomone Labs, and others during the forecast period 2020-2034.

Discover how the nerve growth factor market [https://www.delveinsight.com/sample-request/nerve-growth-factor-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] is rising in the upcoming years

Nerve Growth Factor Companies: Dompe farmaceutici S.p.A., Pfizer Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Merck KGaA, Sanofi, Promega Corporation, and Alomone Labs, and others.

Scope of the Nerve Growth Factor Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Nerve Growth Factor Companies: Dompe farmaceutici S.p.A., Pfizer Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Merck KGaA, Sanofi, Promega Corporation, and Alomone Labs, and others

*
Nerve Growth Factor Therapeutic Assessment: Nerve Growth Factor current marketed and Nerve Growth Factor emerging therapies

*
Nerve Growth Factor Market Dynamics: Nerve Growth Factor market drivers and Nerve Growth Factor market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Nerve Growth Factor Unmet Needs, KOL's views, Analyst's views, Nerve Growth Factor Market Access and Reimbursement

Request for our free sample pages @ https://www.delveinsight.com/report-store/nerve-growth-factor-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Nerve Growth Factor Patient Share (%) Overview at a Glance

5. Nerve Growth Factor Market Overview at a Glance

6. Nerve Growth Factor Disease Background and Overview

7. Nerve Growth Factor Epidemiology and Patient Population

8. Country-Specific Patient Population of Nerve Growth Factor

9. Nerve Growth Factor Current Treatment and Medical Practices

10. Unmet Needs

11. Nerve Growth Factor Emerging Therapies

12. Nerve Growth Factor Market Outlook

13. Country-Wise Nerve Growth Factor Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Nerve Growth Factor Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Nerve Growth Factor Pipeline Insights, DelveInsight

"Nerve Growth Factor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Nerve Growth Factor market. A detailed picture of the Nerve Growth Factor pipeline landscape is provided, which includes the disease overview and Nerve Growth Factor treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nerve-growth-factor-market-epidemiology-therapies-companies-delveinsight-domp-farmaceutici-spa-pfizer-inc-regeneron-pharmaceuticals-inc-astellas-pharma-inc-merck-kgaa-sanofi-promega]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.